With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1211591-88-6,5-(Trifluoromethyl)pyridazin-3-amine,as a common compound, the synthetic route is as follows.
To a solution of 2-[6-(2-bromoacetyl)-5-ethylsulfonyl-3-pyridyl]-2-methyl-propanenitrile (300 mg, 0.84mmol, 1.00 equiv.) [compound 12 prepared as described in step 2, example P1] in acetonitrile (6.3 mL)were added 5-(trifluoromethyl)pyridazine-3-amine (150 mg, 0.88 mmol, 1.00 equiv.) [prepared asdescribed in W02016/051193) and magnesium oxide (67 mg, 1.70 mmol, 2.00 equiv.) at roomtemperature under argon atmosphere. The resulting mixture was heated to 90 C overnight. The reaction mixture was cooled down at room temperature, filtered and concentrated. The crude material was diluted with ethyl acetate and satuared ammonium chloride solution. The aqueous layer was separated and extracted twice with ethyl acetate. The organic layers were combined, dried overanhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography over silica gel (ethyl acetate in cyclohexane) to obtain the title compound. LCMS (method 4): 424 (M+H) retention time: 0.97 mm., 1211591-88-6
The synthetic route of 1211591-88-6 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; SYNGENTA PARTICIPATIONS AG; RENDLER, Sebastian; EDMUNDS, Andrew; MUEHLEBACH, Michel; EMERY, Daniel; RAWAL, Girish; SEN, Indira; SIKERVAR, Vikas; (105 pag.)WO2019/53182; (2019); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem